Achieve Life Sciences, Inc

Achieve Life Sciences' ORCA-OL trial met the FDA's requirement of at least 300 participants completing six months of cytisinicline treatment, a key milestone for NDA submission.

Achieve Life Sciences received FDA agreement on its Phase 3 trial design for cytisinicline as a vaping cessation treatment.

Achieve Life Sciences is developing cytisinicline, a novel treatment for vaping addiction, which has received "breakthrough therapy" designation from the FDA.

Achieve Life Sciences completed enrollment in its Phase 3 ORCA-OL trial, evaluating cytisinicline for smoking and vaping cessation, with 479 participants across 29 U.S. sites.

Achieve Life Sciences completed enrollment in the Phase 3 ORCA-OL trial, evaluating the long-term safety of cytisinicline for smoking and vaping cessation, with positive initial safety review.

Achieve Life Sciences completed enrollment in the ORCA-OL trial, with 479 participants evaluating long-term exposure to cytisinicline for nicotine dependence.

E-cigarettes, initially seen as a smoking cessation tool, have led to a new wave of nicotine addiction, with many users finding it difficult to quit vaping.

Cytisine, a plant-based smoking cessation treatment approved in Canada and the UK, is awaiting FDA approval in the U.S.

Achieve Life Sciences intends to raise up to $50 million through a stock offering, with Jefferies acting as the sales agent, to fund the clinical development of cytisinicline.